Edwards Lifesciences/$EW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Ticker
$EW
Sector
Primary listing
NYSE
Employees
15,800
Headquarters
Website
EW Metrics
BasicAdvanced
$47B
11.52
$7.02
1.05
-
Price and volume
Market cap
$47B
Beta
1.05
52-week high
$83.04
52-week low
$64.89
Average daily volume
4.8M
Financial strength
Current ratio
4.682
Quick ratio
3.534
Long term debt to equity
6.38
Total debt to equity
6.624
Interest coverage (TTM)
80.25%
Profitability
EBITDA (TTM)
1,739.3
Gross margin (TTM)
78.87%
Net profit margin (TTM)
72.96%
Operating margin (TTM)
27.95%
Effective tax rate (TTM)
13.55%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
8.42%
Return on equity (TTM)
15.53%
Valuation
Price to earnings (TTM)
11.518
Price to revenue (TTM)
8.391
Price to book
4.51
Price to tangible book (TTM)
6.26
Price to free cash flow (TTM)
82.547
Free cash flow yield (TTM)
1.21%
Free cash flow per share (TTM)
0.979
Growth
Revenue change (TTM)
9.50%
Earnings per share change (TTM)
188.87%
3-year revenue growth (CAGR)
2.01%
10-year revenue growth (CAGR)
8.86%
3-year earnings per share growth (CAGR)
44.83%
10-year earnings per share growth (CAGR)
26.50%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
Bulls say / Bears say
Second-quarter 2025 revenue rose 11.9% year-over-year to $1.53 billion, surpassing consensus estimates of $1.49 billion and driving a 7.6% share price jump on the back of broad-based segment strength. (Investing.com)
Transcatheter mitral and tricuspid therapies (TMTT) sales surged 61.9% to $134.5 million in Q2, reflecting strong uptake of PASCAL and EVOQUE and early positive feedback on the CE-marked SAPIEN M3 system. (Business Wire)
Following Q2 results, Edwards raised its full-year sales growth guidance to 9–10% and increased its TAVR sales outlook to 6–7%, signaling management’s confidence in sustained market leadership and robust execution. (Business Wire)
U.S. Federal Trade Commission’s lawsuit to block Edwards’ $1.2 billion JenaValve acquisition highlights significant regulatory risk that could delay the company’s expansion into aortic regurgitation therapies and increase legal costs. (Reuters)
Persistent hospital capacity constraints have historically limited the rate of TAVR procedures, suggesting that ongoing logistical bottlenecks may continue to hamper growth in Edwards’ core transcatheter aortic valve replacement business. (MedTech Dive)
Boston Scientific’s decision to discontinue global sales of its Acurate TAVR systems due to heightened regulatory demands underscores the volatility and unpredictability of device approvals, a challenge that Edwards may also face with its newer transcatheter products. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
EW News
AllArticlesVideos
Successful Patient Outcomes Demonstrated With Edwards' SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
Business Wire23 hours ago
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
Business Wire23 hours ago
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
Business Wire5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Edwards Lifesciences stock?
Edwards Lifesciences (EW) has a market cap of $47B as of October 28, 2025.
What is the P/E ratio for Edwards Lifesciences stock?
The price to earnings (P/E) ratio for Edwards Lifesciences (EW) stock is 11.52 as of October 28, 2025.
Does Edwards Lifesciences stock pay dividends?
No, Edwards Lifesciences (EW) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Edwards Lifesciences dividend payment date?
Edwards Lifesciences (EW) stock does not pay dividends to its shareholders.
What is the beta indicator for Edwards Lifesciences?
Edwards Lifesciences (EW) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.